
What if the reason cancer wins isn't the tumor itself, but the silence it forces on your immune system? Aaron Edwards grew up in Henderson, Kentucky, left home at sixteen for a bold academic experiment, and spent a decade in biotech working on some of the most cutting-edge gene therapies in the world before asking himself a hard question: why does promising science so rarely reach patients? That question led him to Harvard, and then to KiraGen Bio, where he and his team are building what he calls "noise-cancelling headphones for cancer therapy." Using gene editing and AI, KiraGen is engineering immune cells that can finally hear through the suppressive environment solid tumors create, and fight back. In this episode, Aaron and Rosa talk about the journey from a small Kentucky town to the frontier of CAR-T cell therapy, what glioblastoma patients and their families need to know right now, and why the future of cancer treatment should show up in your community clinic, not just at elite academic centers. In this episode: Why CAR-T therapy transforms blood cancers but has largely failed solid tumors until now The "noise-cancelling" science behind KiraGen's approach to glioblastoma Aaron's concept of "Ms. Frizzles," the teachers and mentors who invest in potential before the outcome is certain What an off-the-shelf cell therapy library could mean for everyday cancer patients Why $250 million dedicated to pediatric brain tumors could accelerate progress by years Connect with Aaron: Website: kiragenbio.com LinkedIn X
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Invisibly Allergic with author Zoe Slaughter

Building Interoperability with Sandra Johnson

Ep 75: Stop the Splash with Sarah Waimon, Nurse Inventor

Bullying Stops Here with Renee Thompson
Free AI-powered recaps of Nurse Rosa's INsights and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.